GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Outlook Therapeutics Inc (NAS:OTLK) » Definitions » ROC (Joel Greenblatt) %

Outlook Therapeutics (Outlook Therapeutics) ROC (Joel Greenblatt) %

: -12,724.81% (As of Dec. 2023)
View and export this data going back to 2016. Start your Free Trial

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Outlook Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -12,724.81%.

The historical rank and industry rank for Outlook Therapeutics's ROC (Joel Greenblatt) % or its related term are showing as below:

OTLK' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -32738.99   Med: -300.08   Max: -69.77
Current: -32738.99

During the past 10 years, Outlook Therapeutics's highest ROC (Joel Greenblatt) % was -69.77%. The lowest was -32738.99%. And the median was -300.08%.

OTLK's ROC (Joel Greenblatt) % is ranked worse than
96.74% of 1471 companies
in the Biotechnology industry
Industry Median: -339.84 vs OTLK: -32738.99

Outlook Therapeutics's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was -122.40% per year.


Outlook Therapeutics ROC (Joel Greenblatt) % Historical Data

The historical data trend for Outlook Therapeutics's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Outlook Therapeutics Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
ROC (Joel Greenblatt) %
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -318.18 -2,003.00 -5,165.68 -4,384.52 -7,958.42

Outlook Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROC (Joel Greenblatt) % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -8,497.22 -50,187.16 -168,753.49 -212,736.51 -12,724.81

Competitive Comparison

For the Biotechnology subindustry, Outlook Therapeutics's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Outlook Therapeutics ROC (Joel Greenblatt) % Distribution

For the Biotechnology industry and Healthcare sector, Outlook Therapeutics's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Outlook Therapeutics's ROC (Joel Greenblatt) % falls into.



Outlook Therapeutics ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Sep. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 7.587) - (10.257 + 0 + 0.92)
=-3.59

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 10.032) - (8.311 + 0 + 1.113)
=0.608

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Outlook Therapeutics for the quarter that ended in Dec. 2023 can be restated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-41.292/( ( (0.026 + max(-3.59, 0)) + (0.015 + max(0.608, 0)) )/ 2 )
=-41.292/( ( 0.026 + 0.623 )/ 2 )
=-41.292/0.3245
=-12,724.81 %

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Outlook Therapeutics  (NAS:OTLK) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Outlook Therapeutics ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Outlook Therapeutics's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Outlook Therapeutics (Outlook Therapeutics) Business Description

Traded in Other Exchanges
Address
485 Route 1 South Building F, Suite 320, Iselin, NJ, USA, 08852
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications.
Executives
Terry Dagnon officer: Chief Operating Officer C/O ONCOBIOLOGICS, INC., 7 CLARKE DRIVE, CRANBURY NJ 08512
Jeff Evanson officer: Chief Commercial Officer C/O ONCOBIOLOGICS, INC., 7 CLARKE DRIVE, CRANBURY NJ 08512
Yezan Munther Haddadin director ZAHRAN STREET, 7TH CIRCLE ZAHRAN PLAZA, 4TH FLOOR, PO BOX 142904, AMMAN M2 11844
Faisal Ghiath Sukhtian director 7TH CIRCLE, ZAHRAN ST., ZAHRAN PLAZA BLDG,4TH FLR, PO BOX 142909, AMMAN M2 11844
Kurt J Hilzinger director 1300 MORRIS DRIVE, SUITE 100, CHESTERBROOK PA 19087
Julia A Haller director C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Trenary C Russell Iii director, officer: CEO and President 1700 E ST ANDREW PLACE, SANTA ANA CA 92705
Ghiath M. Sukhtian director, 10 percent owner 7TH CIRCLE, ZAHRAN ST., ZAHRAN PLAZA BUILDING, 4TH FLOOR, AMMAN M2 11844
Lawrence A Kenyon officer: CFO and Secretary C/O OUTLOOK THERAPEUTICS, INC., 7 CLARKE DRIVE, CRANBURY NJ 08512
Syntone Ventures Llc 10 percent owner 1517 CHAMPLAIN CREST WAY, CARY NC 27513
Randy H Thurman director 222 MERCHANDISE MART PLAZA, SUITE 2024, CHICAGO IL 60654
Andong Huang director C/O OUTLOOK THERAPEUTICS, INC., 4260 US ROUTE 1, MONMOUTH JUNCTION NJ 08852
Gerd Auffarth director C/O PRESBIA PLC, 120/121 BAGGOT STREET LOWER, DUBLIN 2 L2 00000
Julian S Gangolli director 4955 BASELINE AVENUE, SANTA YNEZ CA 93460
Gms Ventures & Investments director C/O INTERTRUST CORP. SVCS. (CAYMAN) LTD., 190 ELGIN AVENUE, GEORGE TOWN E9 KYI-9007

Outlook Therapeutics (Outlook Therapeutics) Headlines

From GuruFocus